- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01810289
The "START" (a Streamlined ART Initiation Strategy) Study (START-ART)
Visão geral do estudo
Descrição detalhada
RATIONALE: In Africa, up to a 50-75% of HIV-infected, adults fail to initiate (FTI) ART or encounter delays of months even after eligibility through CD4+ T-cell testing or clinical criteria are established. Recent randomized trials including ACTG Protocol 5164, ACTG 5221, CAMELIA and SAPIT have demonstrated that delays of even weeks in ART initiation increases mortality among patients presenting with active opportunistic infections. Even among those without active infections, mortality among untreated persons with a CD4 < 350 approaches 15/100 person-years - a large proportion of which should be avoidable in patients who have presented to care. New dissemination and implementation strategies that are generalizable across resource-limited settings are needed to address FTI and make the public health approach more effective. The overall goal of the multi-component START strategy is to initiate the greatest number of eligible patients in the shortest amount of time possible, while maintaining safety, efficacy and cost effectiveness.
HYPOTHESIS: The START intervention, a combined intervention using provider education, novel technology and reinforcing feedback, will increase the rapidity and completeness of ART initiation.
INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level < 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2) targeted knowledge transfer (i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3) feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.
STUDY DESIGN: A cluster-randomized, step-wedge trail of 20 clinics operated by the Makerere Joint AIDS Program. Four clinic sites will be randomly assigned to the START at 6-month intervals between month six and 24 during the three-year trial.
PRIMARY OBJECTIVE
1. Evaluate the programmatic change of START on the cumulative incidence of ART initiation 14 days after first clinical eligibility for ART in treatment eligible HIV-infected patients receiving care under routine program conditions in a large, multi-site, HIV care program in Uganda.
SECONDARY OBJECTIVES
- Evaluate the effect of START on the incidence of mortality in treatment-eligible, HIV-infected patients.
- Evaluate the effect of START on plasma HIV RNA levels one year after treatment eligibility in HIV-infected patients presenting to care in a multi-site, HIV care program.
- Evaluate the effect of START on the incidence of vertical transmission in all treatment-eligible, HIV-infected women.
- Evaluate the effect of START on retention among ART-eligible, HIV-infected patients in the study sites.
- To assess the cost-effectiveness of the START intervention.
- To evaluate adaptation of START intervention into clinical care through qualitative analysis of counseling interactions and limited interviews with counselors and patients regarding their experience of counseling and identification of content of current counseling activities and how this changes over time.
OUTCOMES: The primary outcome of the study is ART initiation. Secondary outcomes are all-cause mortality, plasma HIV RNA at one year after clinic presentation, vertical transmission events and cost-effectiveness measures.
ANALYTIC PLAN:
Primary analysis for primary outcome:
We will treat the outcome as binary, in which we consider patients as either initiating ARV by 14 days or not. In other words, the outcome of ART start within 14 days or less is met if the start is by 14 days inclusive (<=14 days), otherwise the outcome is not met. Patients with less than 14 days of observation time before cross-over or end of study database closure will not be analyzed. This means that even if a patient initiates ART but has less than 14 days of possible observation time, that event will not be counted. Also, deaths prior to ARV initiation are considered non-initiations. The analysis will use a mixed effect logistic regression model (meglm in Stata 14.0) with a Normal random effect for site and a fixed effect for intervention. Marginal proportions will under intervention and control be calculated using the "margins" command in Stata. We will represent the effect as a risk ratio of marginal proportions.
Secondary sensitivity analyses for primary outcome
- We will adjust the primary analysis for calendar time specified as a restricted cubic spline.
- We will restrict analyses to the incidently eligible population.
- We will perform an analysis including all observation time censoring those with less than 14 days of observation due to database closure or cross-over.
- We will carry out an analysis in which we estimate the effect of crossing into the intervention condition among patients who are eligible but who had not started ART at the time clinics changed from control to intervention through introduction of a time-varying covariate representing cross over date in a multivariable regression model.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- All MJAP-supported clinics in Kampala and Mbarara Districts
Exclusion Criteria:
- None.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: MJAP Clinics Intervention
START intervention.
This is a stepped wedge design so each clinic will experience both conditions.
|
INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level < 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model. This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design. |
Sem intervenção: MJAP Clinics Pre-Intervention
Standard of care.
This is a stepped wedge design so each clinic will experience both conditions.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Cumulative Incidence of ART Initiation 14 Days After Clinical Eligibility in Treatment Eligible HIV-infected Patients
Prazo: 14 days
|
Patients may be ART eligible at the start of the study or become ART eligible for the first time in the 3 year time frame.
|
14 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Incidence of Mortality in Treatment-eligible, HIV-infected Patients.
Prazo: 1 years
|
We ascertained mortality in the subgroup of those selected for HIV RNA assessment.
Vital status is not reliably reported in program data.
Assessment was 1 year after ART eligibility.
|
1 years
|
Retention in HIV Care Among Treatment-eligible, HIV-infected Patients.
Prazo: 1 years
|
Retention was operationalized as the proportion of appointments made within 7 days within one year after ART eligibility.
|
1 years
|
HIV RNA Levels Among Treatment-eligible, HIV-infected Patients One Year Following ART Eligibility
Prazo: 1 year
|
Due to financial constraints, HIV RNA was measured in a random sample of patients to asses virologic suppression.
|
1 year
|
Incidence of Vertical Transmission in All HIV-infected Women Who Are Treatment-eligible During the Study Period.
Prazo: 3 years
|
3 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Moses Kamya, MB.Ch.B, Makerere University
- Investigador principal: Elvin Geng, MD, MPH, University of California, San Francisco
Publicações e links úteis
Publicações Gerais
- Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, Wallenta J, Charlebois E, Camlin C, Kahn J, Chang W, Glidden D, Kamya M, Havlir D, Geng E. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV. 2016 Nov;3(11):e539-e548. doi: 10.1016/S2352-3018(16)30090-X. Epub 2016 Aug 27.
- Hodgson S, Griffin TJ, Reilly C, Harvey S, Witthuhn BA, Sandri BJ, Kunisaki KM, Wendt CH. Plasma sphingolipids in HIV-associated chronic obstructive pulmonary disease. BMJ Open Respir Res. 2017 Apr 3;4(1):e000180. doi: 10.1136/bmjresp-2017-000180. eCollection 2017.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- START-ART
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationConcluídoTeste de HIV do parceiro | Aconselhamento de casal HIV | Comunicação de casal | Incidência de HIVCamarões, República Dominicana, Geórgia, Índia
-
Erasmus Medical CenterAinda não está recrutandoInfecções por HIV | HIV | Infecção por HIV-1 | Infecção HIV IHolanda
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... e outros colaboradoresRecrutamentoHIV | Teste de HIV | Vinculação ao cuidadoÁfrica do Sul
-
National Taiwan UniversityRecrutamento
-
University of Maryland, BaltimoreRetiradoHIV | Transplante de rim | Reservatório de HIV | CCR5Estados Unidos
-
Helios SaludViiV HealthcareDesconhecidoHIV | Infecção por HIV-1Argentina
-
Hospital Clinic of BarcelonaConcluídoInibidores da Integrase, HIV; INIBIDORES DA PROTEASE DO HIVEspanha
Ensaios clínicos em START
-
University of MemphisUSANA Health SciencesRecrutamentoPerda de pesoEstados Unidos
-
Nanyang Technological UniversityNational Kidney Foundation, SingaporeRecrutamentoDoença renal em estágio final | Doença renal terminal | Insuficiência renal terminal em diálise | Doença Renal Terminal em DiáliseCingapura
-
Universidad Santo TomasUniversidad Pública de NavarraConcluídoAtividade física | Transtorno de Déficit de Atenção e Hiperatividade | Comportamento infantil | ComportamentoChile
-
University College CorkConcluídoReação adversa à drogaIrlanda
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); BC Children's Hospital Research... e outros colaboradoresRecrutamentoPráticas parentais | Práticas de coparentalidade | Alimentação Infantil e Comportamentos Dietéticos | Atividade física infantil/brincadeiras ativas/brincadeiras ao ar livre | Tempo de tela infantilCanadá
-
Texas Scottish Rite Hospital for ChildrenRecrutamentoParalisia Cerebral Unilateral | Prontidão escolarEstados Unidos
-
VA Office of Research and DevelopmentRecrutamentoTranstorno por Uso de Substâncias | Doença mental | Encarcerado recentementeEstados Unidos
-
Arizona State UniversityRecrutamento
-
Assistance Publique - Hôpitaux de ParisCIA : CNGE IRMG Association; CNGE : Collège National des Généralistes Enseignants e outros colaboradoresDesconhecido
-
University of Southern CaliforniaRecrutamentoParalisia cerebralEstados Unidos